Micronutrient Deficiencies. An Unmet Need in Heart Failure

Journal of the American College of Cardiology

Volumn 54, Issue 18, 2009, Pages 1660-1673

  Soukoulis, Victor ^a   Dihu, Jamil B ^b   Sole, Michael ^c   Anker, Stefan D ^d,e   Cleland, John ^f   Fonarow, Gregg C ^g   Metra, Marco ^h   Pasini, Evasio ⁱ   Strzelczyk, Theresa ^a   Taegtmeyer, Heinrich ^j   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

^f CASTLE HILL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ IRCCS   (Italy)

^j UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

energy; heart failure; metabolism; micronutrients; nutrition

Indexed keywords

AMINO ACID; CARNITINE; PLACEBO; TAURINE; THIAMINE; TRACE ELEMENT; UBIDECARENONE;

CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ENERGY TRANSFER; EPIGASTRIC DISCOMFORT; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART MUSCLE NECROSIS; HUMAN; MORTALITY; NAUSEA; NONHUMAN; NUTRITIONAL DEFICIENCY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

DIETARY SUPPLEMENTS; ENERGY METABOLISM; HEART FAILURE; HUMANS; MICRONUTRIENTS; MYOCARDIUM;

EID: 70350020285     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.012     Document Type: Review

References (179)

1. McCullough P.A., Philbin E.F., Spertus J.A., Kaatz S., Sandberg K.R., and Weaver W.D. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 (2002) 60-69
2. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
3. O'Connell J.B. The economic burden of heart failure. Clin Cardiol 23 (2000) III6-III10
4. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29 (2008) 2388-2442
5. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12 (2006) e1-e2
6. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22 (2006) 23-45
7. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 53 (2009) e1-e90
8. Fang J., Mensah G.A., Croft J.B., and Keenan N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52 (2008) 428-434
9. Ahmed A., Allman R.M., Fonarow G.C., et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 14 (2008) 211-218
10. Gheorghiade M., and Pang P.S. Acute heart failure syndromes. J Am Coll Cardiol 53 (2009) 557-573
11. Butler J., and Kalogeropoulos A. Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat!. J Am Coll Cardiol 52 (2008) 435-437
12. Taegtmeyer H., Razeghi P., and Young M.E. Alterations in Cardiac Metabolism in Heart Failure (2004), Saunders, Philadelphia, PA
13. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 110 (2004) 894-896
14. Kumar V., Abbas A.K., Fausto N., Robbins S.L., and Cotran R.S. Robbins and Cotran Pathologic Basis of Disease. 7th edition (2005), Elsevier Saunders, Philadelphia, PA
15. Ingwall J.S. ATP and the Heart (2002), Kluwer Academic, Boston, MA 16
16. Taegtmeyer H., Harinstein M.E., and Gheorghiade M. More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 101 (2008) 3E-7E
17. Razeghi P., and Taegtmeyer H. Cardiac remodeling: UPS lost in transit. Circ Res 97 (2005) 964-966
18. Taegtmeyer H. Carbohydrate interconversions and energy production. Circulation 72 (1985) IV1-IV8
19. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 19 (1994) 59-113
20. Taegtmeyer H., Hems R., and Krebs H.A. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 186 (1980) 701-711
21. Witte K.K., and Clark A.L. Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. Heart Fail Rev 11 (2006) 65-74
22. Keith M.E., Walsh N.A., Darling P.B., et al. B-vitamin deficiency in hospitalized patients with heart failure. J Am Diet Assoc 109 (2009) 1406-1410
23. Sole M.J., and Jeejeebhoy K.N. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 3 (2000) 417-424
24. Azari J., Brumbaugh P., Barbeau A., and Huxtable R. Taurine decreases lesion severity in the hearts of cardiomyopathic hamsters. Can J Neurol Sci 7 (1980) 435-440
25. Hamaguchi T., Azuma J., Awata N., et al. Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. Res Commun Chem Pathol Pharmacol 59 (1988) 21-30
26. Ito T., Kimura Y., Uozumi Y., et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44 (2008) 927-937
27. Keith M.E., Ball A., Jeejeebhoy K.N., et al. Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol 17 (2001) 449-458
28. Scholte H.R., Rodrigues Pereira R., de Jonge P.C., et al. Primary carnitine deficiency. J Clin Chem Clin Biochem 28 (1990) 351-357
29. Takahashi R., Asai T., Murakami H., et al. Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. Hypertension 50 (2007) 497-502
30. Takihara K., Azuma J., Awata N., et al. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J 112 (1986) 1278-1284
31. Anker S.D., and Coats A.J. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 115 (1999) 836-847
32. Anker S.D., Steinborn W., and Strassburg S. Cardiac cachexia. Ann Med 36 (2004) 518-529
33. Kalantar-Zadeh K., Block G., Horwich T., and Fonarow G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 (2004) 1439-1444
34. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
35. Allard M.L., Jeejeebhoy K.N., and Sole M.J. The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 11 (2006) 75-82
36. Sole M.J., and Jeejeebhoy K.N. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz 27 (2002) 174-178
37. Olson R.E., and Schwartz W.B. Myocardial metabolism in congestive heart failure. Medicine (Baltimore) 30 (1951) 21-41
38. Ingwall J.S. On the hypothesis that the failing heart is energy starved: lessons learned from the metabolism of ATP and creatine. Curr Hypertens Rep 8 (2006) 457-464
39. Remondino A., Rosenblatt-Velin N., Montessuit C., et al. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 32 (2000) 2025-2034
40. Taegtmeyer H., Wilson C.R., Razeghi P., and Sharma S. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci 1047 (2005) 208-218
41. Rajabi M., Kassiotis C., Razeghi P., and Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12 (2007) 331-343
42. Depre C., Shipley G.L., Chen W., et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 4 (1998) 1269-1275
43. Doenst T., Goodwin G.W., Cedars A.M., Wang M., Stepkowski S., and Taegtmeyer H. Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro. Metabolism 50 (2001) 1083-1090
44. Nascimben L., Ingwall J.S., Lorell B.H., et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44 (2004) 662-667
45. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
46. Brixius K., Reuter H., Bloch W., and Schwinger R.H. Altered hetero- and homeometric autoregulation in the terminally failing human heart. Eur J Heart Fail 7 (2005) 29-35
47. Tang W.H., and Francis G.S. Neurohormonal upregulation in heart failure. Heart Fail Clin 1 (2005) 1-9
48. Zhang M., and Shah A.M. Role of reactive oxygen species in myocardial remodeling. Curr Heart Fail Rep 4 (2007) 26-30
49. Korang K., Milakofsky L., Hare T.A., Hofford J.M., and Vogel W.H. Levels of taurine, amino acids and related compounds in plasma, vena cava, aorta and heart of rats after taurine administration. Pharmacology 52 (1996) 263-270
50. Barshop B.A., and Gangoiti J.A. Analysis of coenzyme Q in human blood and tissues. Mitochondrion 7 Suppl (2007) S89-S93
51. Debska S., Kawecka A., Wojnarowski K., et al. Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 23 (2000) 90-96
52. Harper P., Wadstrom C., and Cederblad G. Carnitine measurements in liver, muscle tissue, and blood in normal subjects. Clin Chem 39 (1993) 592-599
53. Steele P.E., Tang P.H., DeGrauw A.J., and Miles M.V. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am J Clin Pathol 121 Suppl (2004) S113-S120
54. Pepe S., Marasco S.F., Haas S.J., Sheeran F.L., Krum H., and Rosenfeldt F.L. Coenzyme Q10 in cardiovascular disease. Mitochondrion 7 Suppl (2007) S154-S167
55. Sarter B. Coenzyme Q10 and cardiovascular disease: a review. J Cardiovasc Nurs 16 (2002) 9-20
56. Strey C.H., Young J.M., Molyneux S.L., et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179 (2005) 201-206
57. Langsjoen P.H., and Langsjoen A.M. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 18 (2003) 101-111
58. Ghirlanda G., Oradei A., Manto A., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 33 (1993) 226-229
59. Gissi H.F.I., Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1231-1239
60. Hanninen S.A., Darling P.B., Sole M.J., Barr A., and Keith M.E. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol 47 (2006) 354-361
61. Seligmann H., Halkin H., Rauchfleisch S., et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med 91 (1991) 151-155
62. Zenuk C., Healey J., Donnelly J., Vaillancourt R., Almalki Y., and Smith S. Thiamine deficiency in congestive heart failure patients receiving long term furosemide therapy. Can J Clin Pharmacol 10 (2003) 184-188
63. Yui Y., Itokawa Y., and Kawai C. Furosemide-induced thiamine deficiency. Cardiovasc Res 14 (1980) 537-540
64. Harinstein M.E., Berliner J.I., Shah S.J., Taegtmeyer H., and Gheorghiade M. Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients. Am J Ther 15 (2008) 206-213
65. Razeghi P., Myers T.J., Frazier O.H., and Taegtmeyer H. Reverse remodeling of the failing human heart with mechanical unloading. Emerging concepts and unanswered questions. Cardiology 98 (2002) 167-174
66. Crane F.L., Sun I.L., Crowe R.A., Alcain F.J., and Low H. Coenzyme Q10, plasma membrane oxidase and growth control. Mol Aspects Med 15 Suppl (1994) s1-s11
67. Villalba J.M., Navarro F., Cordoba F., et al. Coenzyme Q reductase from liver plasma membrane: purification and role in trans-plasma-membrane electron transport. Proc Natl Acad Sci U S A 92 (1995) 4887-4891
68. Littarru G.P., and Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 37 (2007) 31-37
69. Di Lisa F., Canton M., Menabo R., Dodoni G., and Bernardi P. Mitochondria and reperfusion injury. The role of permeability transition. Basic Res Cardiol 98 (2003) 235-241
70. Papucci L., Schiavone N., Witort E., et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 278 (2003) 28220-28228
71. Weber C., Bysted A., and Holmer G. Coenzyme Q10 in the diet-daily intake and relative bioavailability. Mol Aspects Med 18 Suppl (1997) S251-S254
72. Baggio E., Gandini R., Plancher A.C., Passeri M., and Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 15 Suppl (1994) s287-s294
73. Ishiyama T., Morita Y., Toyama S., Yamagami T., and Tsukamoto N. A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn Heart J 17 (1976) 32-42
74. Folkers K., Langsjoen P., and Langsjoen P.H. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun 182 (1992) 247-253
75. Langsjoen P.H., Vadhanavikit S., and Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A 82 (1985) 4240-4244
76. Folkers K., Vadhanavikit S., and Mortensen S.A. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 82 (1985) 901-904
77. Jameson S. Statistical data support prediction of death within 6 months on low levels of coenzyme Q10 and other entities. Clin Investig 71 (1993) S137-S139
78. Molyneux S.L., Florkowski C.M., George P.M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 52 (2008) 1435-1441
79. Jeejeebhoy F., Keith M., Freeman M., et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 143 (2002) 1092-1100
80. Belardinelli R., Mucaj A., Lacalaprice F., et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 27 (2006) 2675-2681
81. Morisco C., Trimarco B., and Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 71 (1993) S134-S136
82. Langsjoen H., Langsjoen P., Willis R., and Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 15 Suppl (1994) s165-s175
83. Langsjoen P.H., and Folkers K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin Investig 71 (1993) S140-S144
84. Langsjoen P.H., Langsjoen A., Willis R., and Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 18 Suppl (1997) S145-S151
85. Munkholm H., Hansen H.H., and Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors 9 (1999) 285-289
86. Keogh A., Fenton S., Leslie C., et al. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ 12 (2003) 135-141
87. Khatta M., Alexander B.S., Krichten C.M., et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 132 (2000) 636-640
88. Watson P.S., Scalia G.M., Galbraith A., Burstow D.J., Bett N., and Aroney C.N. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 33 (1999) 1549-1552
89. Sinatra S.T. Coenzyme Q10 and congestive heart failure. Ann Intern Med 133 (2000) 745-746
90. Sander S., Coleman C.I., Patel A.A., Kluger J., and White C.M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12 (2006) 464-472
91. Soja A.M., and Mortensen S.A. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 18 Suppl (1997) S159-S168
92. Mortensen S.A. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"-a multinational trial. Biofactors 18 (2003) 79-89
93. Siliprandi N., Di Lisa F., and Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5 Suppl 1 (1991) 11-15
94. Arsenian M.A. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40 (1997) 265-286
95. Schonekess B.O., Allard M.F., and Lopaschuk G.D. Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77 (1995) 726-734
96. Russell III R.R., Mommessin J.I., and Taegtmeyer H. Propionyl-L-carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol 268 (1995) H441-H447
97. Kendler B.S. Supplemental conditionally essential nutrients in cardiovascular disease therapy. J Cardiovasc Nurs 21 (2006) 9-16
98. Masumura Y., Kobayashi A., and Yamazaki N. Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. Jpn Circ J 54 (1990) 1471-1476
99. Regitz V., Shug A.L., and Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 65 (1990) 755-760
100. Siliprandi N., Di Lisa F., Pivetta A., Miotto G., and Siliprandi D. Transport and function of L-carnitine and L-propionylcarnitine: relevance to some cardiomyopathies and cardiac ischemia. Z Kardiol 76 Suppl 5 (1987) 34-40
101. The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 20 (1999) 70-76
102. Anand I., Chandrashekhan Y., De Giuli F., et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12 (1998) 291-299
103. Loster H., Miehe K., Punzel M., Stiller O., Pankau H., and Schauer J. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 13 (1999) 537-546
104. Mancini M., Rengo F., Lingetti M., Sorrentino G.P., and Nolfe G. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 42 (1992) 1101-1104
105. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139 (2000) S120-S123
106. Iliceto S., Scrutinio D., Bruzzi P., et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 26 (1995) 380-387
107. Voskoboyev A.I., and Ostrovsky Y.M. Thiamin pyrophosphokinase: structure, properties, and role in thiamin metabolism. Ann N Y Acad Sci 378 (1982) 161-176
108. Pannunzio P., Hazell A.S., Pannunzio M., Rao K.V., and Butterworth R.F. Thiamine deficiency results in metabolic acidosis and energy failure in cerebellar granule cells: an in vitro model for the study of cell death mechanisms in Wernicke's encephalopathy. J Neurosci Res 62 (2000) 286-292
109. Sica D.A. Loop diuretic therapy, thiamine balance, and heart failure. Congest Heart Fail 13 (2007) 244-247
110. Roman G.C. Nutritional disorders of the nervous system. In: Shils M.E., and Shike M. (Eds). Modern Nutrition in Health and Disease. 10th edition (2006), Lippincott Williams & Wilkins, Philadelphia, PA 1368-1369
111. Yoshitoshi Y., Shibata N., and Yamashita S. Experimental studies on the beriberi heart. I. Cardiac lesions in thiamine deficient rats. Jpn Heart J 2 (1961) 42-64
112. Singleton C.K., and Martin P.R. Molecular mechanisms of thiamine utilization. Curr Mol Med 1 (2001) 197-207
113. Iwata H. Catecholamine metabolism in thiamine-deficient rats. J Nutr Sci Vitaminol (Tokyo) 22 Suppl (1976) 25-27
114. Boullin D.J. Pharmacological responses of thiamine-deficient rat tissues. Br J Pharmacol Chemother 20 (1963) 190-203
115. Yamashita S. Relationship between thiamine deficient cardiac lesions and myocardial and blood pyruvic acid contents. Jpn Heart J 12 (1971) 474-485
116. Aldinger E.E. Effect of thiamine deficiency on potential myocardial contractility. Circ Res 16 (1965) 238-243
117. Hirota Y., Kane R.L., and Abelmann W.H. Cardiovascular effects of exercise in hamsters with experimental thiamine deficiency. Jpn Circ J 43 (1979) 99-106
118. Cohen E.M., Abelmann W.H., Messer J.V., and Bing H.L. Mechanical properties of rat cardiac muscle during experimental thiamine deficiency. Am J Physiol 231 (1976) 1390-1394
119. Cappelli V., Bottinelli R., Polla B., and Reggiani C. Altered contractile properties of rat cardiac muscle during experimental thiamine deficiency and food deprivation. J Mol Cell Cardiol 22 (1990) 1095-1106
120. Davies M.J., and Jennings R.B. The ultrastructure of the myocardium in the thiamine-deficient rat. J Pathol 102 (1970) 87-95
121. Zangen A., and Shainberg A. Thiamine deficiency in cardiac cells in culture. Biochem Pharmacol 54 (1997) 575-582
122. Brady J.A., Rock C.L., and Horneffer M.R. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc 95 (1995) 541-544
123. Kwok T., Falconer-Smith J.F., Potter J.F., and Ives D.R. Thiamine status of elderly patients with cardiac failure. Age Ageing 21 (1992) 67-71
124. Pfitzenmeyer P., Guilland J.C., d'Athis P., Petit-Marnier C., and Gaudet M. Thiamine status of elderly patients with cardiac failure including the effects of supplementation. Int J Vitam Nutr Res 64 (1994) 113-118
125. Yue Q.Y., Beermann B., Lindstrom B., and Nyquist O. No difference in blood thiamine diphosphate levels between Swedish Caucasian patients with congestive heart failure treated with furosemide and patients without heart failure. J Intern Med 242 (1997) 491-495
126. Shimon I., Almog S., Vered Z., et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 98 (1995) 485-490
127. Smithline H.A. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med 25 (2007) 124-126
128. Witte K.K., Desilva R., Chattopadhyay S., Ghosh J., Cleland J.G., and Clark A.L. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 (2004) 924-930
129. Azuma J., Sawamura A., and Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 56 (1992) 95-99
130. Satoh H., and Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol 30 (1998) 451-463
131. Kramer J.H., Chovan J.P., and Schaffer S.W. Effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol 240 (1981) H238-H246
132. Schaffer S.W., Kramer J., and Chovan J.P. Regulation of calcium homeostasis in the heart by taurine. Fed Proc 39 (1980) 2691-2694
133. Ogarsawa M., Nakamura T., Koyoma I., Nemoto M., and Yoshida T. Reactivity of taurine with aldehydes and its physiologic role. In: Huxtable R., and Michallk D.V. (Eds). Taurine in Health and Disease. Advances in Experimental Biology (1994), Plenum, New York, NY
134. Grimble R.F., Jackson A.A., Persaud C., Wride M.J., Delers F., and Engler R. Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet. J Nutr 122 (1992) 2066-2073
135. Schaffer S., Solodushko V., Pastukh V., Ricci C., and Azuma J. Possible cause of taurine-deficient cardiomyopathy: potentiation of angiotensin II action. J Cardiovasc Pharmacol 41 (2003) 751-759
136. Huxtable R.J., Chubb J., and Azari J. Physiological and experimental regulation of taurine content in the heart. Fed Proc 39 (1980) 2685-2690
137. Schuller-Levis G.B., and Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 226 (2003) 195-202
138. Ganapathy V., and Leibach F.H. Expression and regulation of the taurine transporter in cultured cell lines of human origin. Adv Exp Med Biol 359 (1994) 51-57
139. Crass III M.F., and Lombardini J.B. Loss of cardiac muscle taurine after acute left ventricular ischemia. Life Sci 21 (1977) 951-958
140. Schaffer S.W., Allo S., and Mozaffari M. Potentiation of myocardial ischemic injury by drug-induced taurine depletion. Adv Exp Med Biol 217 (1987) 151-158
141. Corsetti G., Pasini E., D'Antona G., et al. Morphometric changes induced by amino acid supplementation in skeletal and cardiac muscles of old mice. Am J Cardiol 101 (2008) 26E-34E
142. Pasini E., Scarabelli T.M., D'Antona G., and Dioguardi F.S. Effect of amino acid mixture on the isolated ischemic heart. Am J Cardiol 93 (2004) 30A-34A
143. Scognamiglio R., Testa A., Aquilani R., Dioguardi F.S., and Pasini E. Impairment in walking capacity and myocardial function in the elderly: is there a role for nonpharmacologic therapy with nutritional amino acid supplements?. Am J Cardiol 101 (2008) 78E-81E
144. Aquilani R., Viglio S., Iadarola P., et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 101 (2008) 104E-110E
145. Aquilani R., Opasich C., Gualco A., et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail 10 (2008) 1127-1135
146. Brosnan J.T., and Brosnan M.E. Creatine: endogenous metabolite, dietary, and therapeutic supplement. Annu Rev Nutr 27 (2007) 241-261
147. Beer M., Seyfarth T., Sandstede J., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 40 (2002) 1267-1274
148. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997) 2190-2196
149. Shen W., Spindler M., Higgins M.A., et al. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol 39 (2005) 537-544
150. Smith C.S., Bottomley P.A., Schulman S.P., Gerstenblith G., and Weiss R.G. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation 114 (2006) 1151-1158
151. Ferraro S., Codella C., Palumbo F., et al. Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo. Clin Cardiol 19 (1996) 699-703
152. Gordon A., Hultman E., Kaijser L., et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 30 (1995) 413-418
153. Kuethe F., Krack A., Richartz B.M., and Figulla H.R. Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie 61 (2006) 218-222
154. Weber K.T., Simpson R.U., and Carbone L.D. Vitamin D and calcium dyshomoeostasis-associated heart failure. Heart 94 (2008) 540-541
155. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., and Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 41 (2003) 105-112
156. Maiya S., Sullivan I., Allgrove J., et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. Heart 94 (2008) 581-584
157. Weishaar R.E., and Simpson R.U. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 253 (1987) E675-E683
158. Weber K.T., Weglicki W.B., and Simpson R.U. Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res 81 (2009) 500-508
159. Eichhorn E.J., Tandon P.K., DiBianco R., et al. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. J Am Coll Cardiol 21 (1993) 634-640
160. Gottlieb S.S., Baruch L., Kukin M.L., Bernstein J.L., Fisher M.L., and Packer M. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 16 (1990) 827-831
161. Iezhitsa I.N. Potassium and magnesium depletions in congestive heart failure-pathophysiology, consequences and replenishment. Clin Calcium 15 (2005) 123-133
162. Ripa S., Ripa R., and Giustiniani S. Are failured cardiomyopathies a zinc-deficit related disease?. A study on Zn and Cu in patients with chronic failured dilated and hypertrophic cardiomyopathies. Minerva Med 89 (1998) 397-403
163. de Lorgeril M., and Salen P. Selenium and antioxidant defenses as major mediators in the development of chronic heart failure. Heart Fail Rev 11 (2006) 13-17
164. Boldery R., Fielding G., Rafter T., Pascoe A.L., and Scalia G.M. Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy. Heart Lung Circ 16 (2007) 123-126
165. Briet F., Keith M., Leong-Poi H., et al. Triple nutrient supplementation improves survival, infarct size and cardiac function following myocardial infarction in rats. Nutr Metab Cardiovasc Dis 18 (2008) 691-699
166. Witte K.K., Nikitin N.P., Parker A.C., et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26 (2005) 2238-2244
167. Fox K., Ford I., Steg P.G., Tendera M., and Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 807-816
168. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
169. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
170. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
171. Bello D., Shah D.J., Farah G.M., et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 (2003) 1945-1953
172. Cleland J.G., Pennell D.J., Ray S.G., et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362 (2003) 14-21
173. Seghatol F.F., Shah D.J., Diluzio S., et al. Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 93 (2004) 854-859
174. Shors S.M., Cotts W.G., Pavlovic-Surjancev B., et al. Non-invasive cardiac evaluation in heart failure patients using magnetic resonance imaging: a feasibility study. Heart Fail Rev 10 (2005) 265-273
175. Rahimtoola S.H. Concept and evaluation of hibernating myocardium. Annu Rev Med 50 (1999) 75-86
176. Klein L., Gattis W.A., Borrello F., Wu E., O'Connor C.M., and Gheorghiade M. Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. Am J Cardiol 93 (2004) 44A-46A
177. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
178. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
179. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007